Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on September 15, 2021. The filing serves as a Regulation FD disclosure regarding the Company's scheduled participation in the 2021 Baird Global Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing discloses a planned presentation by CEO Richard King regarding clinical development programs.
Guidance, Outlook, and Management Commentary
- Event: The Company will present at the 2021 Baird Global Healthcare Conference on September 15, 2021, at 1:25 pm ET.
- Presenter: Richard King, Chief Executive Officer.
- Topics: The presentation will cover clinical development programs for tildacerfont in the treatment of classic congenital adrenal hyperplasia and polycystic ovary syndrome.
- Exhibit: A slide presentation is included as Exhibit 99.1.
- Legal Status: Information in this Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" under the Exchange Act, nor incorporated by reference into Securities Act filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the slide presentation (Exhibit 99.1) for specific clinical trial data or timelines.
- Confirm the Company's status as an emerging growth company (indicated as yes in the filing).
- Review subsequent filings for any updates on the clinical programs mentioned in the conference presentation.